• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vistagen Therapeutics Inc (NQ: VTGN )

    3.660 -0.040 (-1.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 62,576
    Open 3.750
    Bid (Size) 3.570 (2)
    Ask (Size) 3.650 (3)
    Prev. Close 3.700
    Today's Range 3.550 - 3.750
    52wk Range 1.630 - 24.71
    Shares Outstanding 9,362,444
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
    From Vistagen
    Via Business Wire

    Performance

    YTD
    -28.93%
    -28.93%
    1 Month
    +13.66%
    +13.66%
    3 Month
    -23.11%
    -23.11%
    6 Month
    -20.78%
    -20.78%
    1 Year
    +95.72%
    +95.72%

    More News

    Read More
    InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Receives Mental Health America’s Highest Honor
    Via Investor Brand Network
    Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
    From Vistagen
    Via Business Wire
    TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update
    Via Investor Brand Network
    VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024
    Via InvestorPlace
    Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
    From Vistagen
    Via Business Wire
    BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call
    Via Investor Brand Network
    Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
    From Vistagen
    Via Business Wire
    TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference
    Via Investor Brand Network
    Vistagen to Present at the Jefferies Global Healthcare Conference
    From Vistagen
    Via Business Wire
    BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference
    Via Investor Brand Network
    Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
    From Vistagen
    Via Business Wire
    3 Must-Have Penny Stocks to Boost Your 2024 Portfolio
    Via InvestorPlace
    Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence
    Via InvestorPlace
    InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference
    Via Investor Brand Network
    Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
    From Vistagen
    Via Business Wire
    InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement
    Via Investor Brand Network
    Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
    From Vistagen
    Via Business Wire
    7 Stocks Under $15 Predicted to Boom in the Next 2 Years
    Via InvestorPlace
    Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
    Via InvestorPlace
    InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference
    Via Investor Brand Network
    Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
    From Vistagen
    Via Business Wire
    InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
    Via Investor Brand Network
    Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
    From Vistagen
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.